The News of Us
  • Home
  • Business
  • Politics
  • Science and Technology
  • Health
  • Subscribe Us
No Result
View All Result
The News of Us
  • Home
  • Business
  • Politics
  • Science and Technology
  • Health
  • Subscribe Us
No Result
View All Result
The News of Us
No Result
View All Result

Regeneron Gets Emergency U.S. Clearance for Covid-19 Therapy

Regeneron Pharmaceuticals Inc.’s antibody cocktail received an emergency-use authorization from U.S. drug regulators for treatment of early Covid-19 symptoms, adding to the expanding arsenal of therapies available to physicians at a time when the virus is surging.

Regeneron’s treatment was given to President Donald Trump last month after he contracted Covid-19. While Trump received a number of drugs to combat the virus, he said after he was released from the hospital he expected speedy authorization of Regeneron’s therapy, crediting it with his recovery.

The company said in a statement on Saturday that its therapy, called REGN-COV2, had been authorized for the treatment of mild to moderate Covid-19 in adults and some children of at least 12 years of age. A similar antibody therapy made by Eli Lilly & Co. received emergency clearance from the FDA on Nov. 9.

The FDA’s decision comes as U.S. cases, hospitalizations and deaths all trend upward, and as other drugmakers race to win emergency clearance for experimental vaccines. New cases in the U.S. have topped 100,000 each day since Nov. 5., and on Saturday surpassed 12 million since the start of the pandemic.

“The FDA remains committed to advancing the nation’s public health during this unprecedented pandemic,” Commissioner Stephen Hahn said in the statement. “Authorizing these monoclonal antibody therapies may help outpatients avoid hospitalization and alleviate the burden on our health care system.”

While antibody therapies have been hailed by U.S. infectious-disease chief Anthony Fauci and others as a potential bridge to a vaccine, their emergency clearance comes at a time when the spike in cases and a strained virus-testing system are running up against what is expected to be a limited supply of the therapies.

Regeneron said in its statement Saturday it expects to have treatment doses ready for approximately 80,000 patients by the end of this month, about 200,000 patients by the first week of January, and about 300,000 patients total by the end of January.

The cocktail treatment consists of two monoclonal antibodies that target the spike protein used by the virus to enter cells. Trial findings released by the company in October showed that the drug may help treat patients outside the hospital, reducing virus levels and the need for further medical care.

The therapy appeared to be most beneficial in the subset of patients who hadn’t yet produced coronavirus antibodies on their own, the company has said.

Regeneron, based in Tarrytown, New York, has clinched a $450 million supply deal from Operation Warp Speed, the U.S. government’s program to accelerate vaccines and treatments for Covid-19. The company has said it will make its therapy available at no cost to patients.

[Read More…]

Previous Post

Astronomers Discover Powerful, Newborn, Radio-Emitting Jets in Distant Galaxies

Next Post

U.S. should look at how other high-income countries regulate health care costs: study

Related Posts

Health

Netflix’s The Fall Of The House Of Usher Fires Star Frank Langella Following Misconduct Investigation

Health

Democrats playing into Putin’s hands when it comes to US energy production: experts

Health

Transplant’s Dr. Bishop Sets The Record Straight About His Restrictions In Tense New Episode Clip

Health

‘Pizza eggs’ gain steam on TikTok as a protein-packed dish: ‘Pair well’

Health

Skippy peanut butter recalled because of possible stainless steel fragments

Health

A family suffered weeks of dizziness and nausea. A doctor’s hunch uncovered the cause.

Next Post

U.S. should look at how other high-income countries regulate health care costs: study

Follow us for latest Business News | Political News | Science & Technology News | Health News.

Subscribe Us

By clicking subscribe, I authorize: (1) The News Of Us to use and share my information in accordance with its Terms of Service and Privacy Policy, and (2) The News Of Us or third-party companies, including The News Of Us’s business partners, to contact me by email with offers for goods and services at the email address provided. Please note that the information you have provided to us may be supplemented with additional information obtained from other sources.
Loading

© 2021 The News of Us, - All Rights Reserved.

  • Subscribe Us
  • Contact Us
  • Unsubscribe
  • Privacy Policy
  • Terms Of Service
No Result
View All Result
  • Home
  • Business
  • Politics
  • Science and Technology
  • Health
  • Subscribe Us

© 2021 The News of Us, - All Rights Reserved.